Sökning: WFRF:(Enblad G ) >
High-dose therapy w...
-
Blystad, A K
(författare)
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
- Artikel/kapitelEngelska2001
Förlag, utgivningsår, omfång ...
-
2001-05-04
-
Springer Science and Business Media LLC,2001
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-485671
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-485671URI
-
https://doi.org/10.1038/sj.bmt.1702867DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Peripheral T cell lymphomas (PTCL) have a poorer prognosis after conventional treatment than do high-grade B cell lymphomas. The place for high-dose therapy (HDT) with autologous stem cell support in these patients is still not clear. Forty patients, 10 women and 30 men, median age 41.5 years (range 16-61) with PTCL were treated with HDT and autologous stem cell support at The Norwegian Radium Hospital, Oslo, Norway and The University Hospital, Uppsala, Sweden, between February 1990 and September 1999. The histologic subtypes were: PTCL unspecified, 20 patients; intestinal, two patients; angioimmunoblastic (AILD), two patients; angiocentric, two patients and anaplastic large cell lymphoma (ALCL), 14 patients. All patients had chemosensitive disease and had received anthracycline-containing regimens prior to transplantation. At the time of HDT, 17 patients were in first PR or CR and 23 were in second or third PR or CR. Conditioning regimens were BEAM in 15 patients, BEAC in 14 patients, cyclophosphamide and total body irradiation (TBI) in eight patients, BEAC, without etoposide and TBI in one patient and mitoxantrone and melphalan in two patients. There were three (7.5%) treatment-related deaths. The estimated overall survival (OS) at 3 years was 58%, the event-free survival (EFS) 48% and the relapse-free survival (RFS) 56%, with a median follow-up of 36 months (range 7-100) for surviving patients. The patients with ALCL tended to have a better prognosis compared to those with other PTCL subtypes, OS 79% vs 44%, respectively. In conclusion, patients with chemosensitive PTCL who are failing to achieve CR with first-line chemotherapy or are in relapse can successfully be treated with HDT and autologous stem cell support.
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Enblad, G
(författare)
-
Kvaløy, S
(författare)
-
Berglund, A
(författare)
-
Delabie, J
(författare)
-
Holte, H
(författare)
-
Carlson, K
(författare)
-
Kvalheim, G
(författare)
-
Bengtsson, MUppsala universitet,Enheten för klinisk immunologi
(författare)
-
Hagberg, H
(författare)
-
Uppsala universitetEnheten för klinisk immunologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Bone Marrow Transplantation: Springer Science and Business Media LLC27:7, s. 711-60268-33691476-5365
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Blystad, A K
-
Enblad, G
-
Kvaløy, S
-
Berglund, A
-
Delabie, J
-
Holte, H
-
visa fler...
-
Carlson, K
-
Kvalheim, G
-
Bengtsson, M
-
Hagberg, H
-
visa färre...
- Artiklar i publikationen
-
Bone Marrow Tran ...
- Av lärosätet
-
Uppsala universitet